Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK

Payment Information We Accept Visa, Mastercard, American Express and Discover

 

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Abbott Q1 ’22 earnings update; New YouTube video featuring Libre 2 app

Here is a brief preview of this blast: Abbott hosted its Q1 '22 earnings call (press release; view infographic) and provided updates on its Libre business. Unsurprisingly, much of the call focused on Abbott’s COVID-19 testing and business recovery. Of note, Abbott reported that the WW Libre user base has reached ~4M users. Separately, Abbott recently posted a new Libre 2 smartphone compatibility video on the company’s FreeStyle US YouTube channel (view video). Below are diabetes-related highlights from the call as well as insights regarding Abbott’s newly posted video.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.